Edwards Lifesciences Corp
EWEdwards Lifesciences Corp (EW) specializes in medical technologies primarily focused on heart valve disease and critical care monitoring. The company is known for its innovations in minimally invasive heart valve repair and replacement, including transcatheter aortic valve replacement (TAVR) devices, as well as advanced hemodynamic monitoring systems. Founded in 1958, Edwards Lifesciences is a leading player in the cardiovascular medical device industry, dedicated to improving patient outcomes through innovative solutions.
Company News
The transcatheter heart valve replacement market is projected to grow from $6.40 billion in 2025 to $19.98 billion by 2033, with a 15.32% CAGR, driven by rising valvular heart disease prevalence and preference for minimally invasive cardiac procedures.
The Federal Trade Commission (FTC) is blocking Edwards Lifesciences' proposed acquisition of JenaValve Technology, arguing the deal would eliminate competition in transcatheter aortic valve replacement (TAVR-AR) devices and potentially reduce innovation and patient options.
HOLX vs. EW: Which Stock Is the Better Value Option?
Mixed performance in the healthcare sector as Eli Lilly dominates. Edwards Lifesciences excels in transcatheter heart valve replacement and EPS growth. Read more here.
